Disease · MONDO_0008171

nephrolithiasis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. nephrolithiasis. Diseases, record MONDO_0008171. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0008171

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: nephrolithiasis; Open Targets
Open Targets ID: MONDO_0008171; Open Targets
Other names: Calculi, Kidney, Calculi, Renal, Calculus, Kidney, Calculus, Renal, Kidney Calculi, Kidney Calculus, Kidney Stones, Renal Calculus, Renal stones, Stone, Kidney, Stones, Kidney, calculus of kidney and ureter, kidney stone, renal calculi; Open Targets
Disease Ontology: DOID:585; Disease Ontology
MeSH: D053040; MeSH
NCI Thesaurus: C114667; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 26 drugs, from TTD; Open Targets

Drugs26

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
POTASSIUM CITRATE	CHEMBL3989822	Small molecule	Approval	TTD	3	2	2	Drugs and targets
POTASSIUM ACETATE	CHEMBL1201058	Small molecule	Approval	TTD	1	0	0	Drugs and targets
TAMSULOSIN	CHEMBL836	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
FUROSEMIDE	CHEMBL35	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
ACETAMINOPHEN	CHEMBL112	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ALFUZOSIN	CHEMBL709	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
DOXAZOSIN	CHEMBL707	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
KETOROLAC	CHEMBL469	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
LANTHANUM CARBONATE	CHEMBL2096647	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
NIFEDIPINE	CHEMBL193	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 26

See all 26 drugs

Targets21

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRA1A	Adrenergic receptor alpha-1	5	Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist; Alpha-1a adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor alpha-1	4	Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist	Phase 3	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor alpha-1	4	Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist	Phase 3	https://conductscience.org/library/genes/146	Drugs and targets
OPRM1	Mu-type opioid receptor	2	Mu opioid receptor agonist	Phase 3	https://conductscience.org/library/genes/4988	Drugs and targets
PTGS1	Cyclooxygenase	2	Cyclooxygenase inhibitor	Phase 3	https://conductscience.org/library/genes/5742	Drugs and targets
PTGS2	Cyclooxygenase	2	Cyclooxygenase inhibitor	Phase 3	https://conductscience.org/library/genes/5743	Drugs and targets
SLC12A3	Solute carrier family 12 member 3	2	Thiazide-sensitive sodium-chloride cotransporter inhibitor	Unknown	https://conductscience.org/library/genes/6559	Drugs and targets
ADRB1	Adrenergic receptor beta	1	Adrenergic receptor beta agonist	Phase 2	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Adrenergic receptor beta	1	Adrenergic receptor beta agonist	Phase 2	https://conductscience.org/library/genes/154	Drugs and targets
ADRB3	Adrenergic receptor beta	1	Adrenergic receptor beta agonist	Phase 2	https://conductscience.org/library/genes/155	Drugs and targets

1 to 10 of 21

See all 21 targets

Trials23

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03584373	Pain Outcomes of Non-opioid vs. Opioid Analgesia for Kidney Stone Surgery.	Phase 3	119	2023-12-18	Nephrolithiasis	ACETAMINOPHEN, KETOROLAC, OXYCODONE	Its record names the disease	ClinicalTrials.gov
NCT00209131	Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy	Not applicable	24	2012-07-09	Urolithiasis	TAMSULOSIN	Its record names the disease	ClinicalTrials.gov
NCT05270421	Effect of Furosemide on ESWL Outcomes for Renal and Ureteral Calculi	Phase 3	500		Urolithiasis, Nephrolithiasis, Urinary Calculi, Ureterolithiasis	FUROSEMIDE	Its record names the disease	ClinicalTrials.gov
NCT05916963	Impact of Forced Diuresis on the Residual Fragment Rate After Flexible Ureteroscopy for Destruction of Kidney Stones With Laser	Phase 3	374		Kidney Stone	FUROSEMIDE	Its record names the disease	ClinicalTrials.gov
NCT00713739	Alfuzosin for Medical Expulsion Therapy of Ureteral Stones	Phase 3	240		Kidney Stones	ALFUZOSIN, DOXAZOSIN, NIFEDIPINE, PRAZOSIN	Its record names the disease	ClinicalTrials.gov
NCT05032287	Medical Expulsive Therapy Post-SWL For Renal Stones	Not applicable	235		Urologic Diseases, Urolithiasis, Stone, Kidney	TAMSULOSIN	Its record names the disease	ClinicalTrials.gov
NCT04367155	Efficacy of Tranexamic Acid on Blood Loss During Percutaneous Nephrolithotomy.	Not applicable	200		Renal Stones, Nephrolithiasis	TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT07336485	Impact of Forced Diuresis on the Residual Fragment Rate After Flexible Ureteroscopy for Management of Renal Stones	Not applicable	200		Kidney Stones	FUROSEMIDE	Its record names the disease	ClinicalTrials.gov
NCT01215708	Effects of the Use of Adjuvant Drugs After Extracorporeal Shockwave Lithotripsy (ESWL) in Renal Calculus	Phase 3	136		Renal Calculi	TAMSULOSIN	Its record names the disease	ClinicalTrials.gov
NCT00860093	Efficacy and Safety of Using MPC-5971 in Subjects Undergoing Shock Wave Lithotripsy	Phase 2	135		Nephrolithiasis	MPC-5971	Its record names the disease	ClinicalTrials.gov

1 to 10 of 23

See all 23 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Non-Opioid Analgesia vs Opioid Analgesia: deaths from any cause	0 of 51	0 of 54	105	NCT03584373	Trial comparisons
Non-Opioid Analgesia vs Opioid Analgesia: serious adverse events	5 of 51	7 of 54	105	NCT03584373	Trial comparisons
Non-Opioid Analgesia vs Opioid Analgesia: Rates of Constipation	11 of 44	17 of 46	90	NCT03584373	Trial comparisons

Papers from its trials5

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40194294	DERIVED	1	PubMed
38965611	DERIVED	1	PubMed
37882229	DERIVED	1	PubMed
36261757	DERIVED	1	PubMed
35710560	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0008171

GET https://conductscience.org/api/diseases/v1/MONDO_0008171/drugs?page=2

API reference For AI assistants